# ONGC

Emkay<sup>®</sup>

Refer to important disclosures at the end of this report

# Gas realizations to follow rising oil prices; KG 98/2 ramp-up starts

- Oil prices near USD70/bbl and the rise in broader energy complex augur well for ONGC. Our FY22/23 earnings estimates and TP of Rs130 are based on assumption of USD55-56/bbl Brent prices, and hence they have a material upside.
- We estimate a 58% increase in the domestic gas price to USD2.8/mmbtu GCV in Oct'21 as global gas benchmarks strengthen. Current Alberta-Henry Hub rates at USD2.5-3.0/mmbtu and NBP near USD10 imply a spot realization of USD4.4/mmbtu for ONGC.
- ONGC's bidding for 2mmscmd of KG 98/2 gas is underway. While the current ceiling is USD3.6/mmbtu, we estimate it to jump to USD6-7/mmbtu in Oct'21 (closer to 10.5% of Brent slope sought) due to the rise in prices of alternate fuels (naphtha-FO) and LNG.
- The 2mmscmd first 98/2 bidding round is likely to be followed by a larger 5mmscmd round toward the year end, thereby adding over 10% to current output. Hence, ONGC could enter a cycle of production growth along with higher realization. Retain Buy (OW stance).

**Oil prices firm near USD70/bbl on global recovery, OPEC+ discipline:** Brent prices continue to hover near USD70/bbl, driven by the prospects of a global demand recovery and OPEC+'s production discipline. Positive near-term demand-supply balance with inventory destocking would provide support and unless the OPEC+ deal breaks down, a significant downside risk to oil prices is low. Our current Brent price assumption is USD55/56 for FY22/23, though there is an upside risk to the same. Every USD5/bbl increase in oil realization improves ONGC's FY22E EPS by Rs3 per share or 22%.

**Broad-based increase in gas prices expected based on current formula:** While we are cautiously optimistic on domestic gas pricing reforms, we estimate a 58% rise in formula prices due to the rise in global gas benchmarks. In fact current rates imply a USD4.4/mmbtu spot price, which it is 2.5x of prevailing USD1.79/mmbtu, GCV. Rise in prices of alternate fuels like naphtha, FO and coal and LNG implies that deep water HP-HT ceiling should also increase from USD3.6/mmbtu to USD6-7/mmbtu, GCV in H2FY22. This would boost KG-DWN-98/2 gas realization for ONGC.

**ONGC may see double-digit growth in gas output next year:** ONGC's first tender of 2mmscmd of KG 98/2 gas is under bidding and supplies are expected to start by Jul'21. ONGC has sought 10.5% of Brent with a term of 3 to 5 years. As per media reports, this would be followed by a larger 5mmscmd offer by Dec'21. A total of 7mmscmd is over 10% of ONGC's current gas output, thereby leading to a sizeable production growth in CY22. ONGC has envisaged 15mmscmd of peak output from 98/2.

**Valuation:** We value ONGC's standalone business at 4x FY23E EV/EBITDA and listed investments at a 50% holdco discount to arrive at a TP of Rs130/sh.

Please see our sector model portfolio (Emkay Alpha Portfolio): Oil & Gas (page 6)

#### Financial Snapshot (Standalone)

(Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Revenue	1,096,546	962,136	682,911	857,688	903,980
EBITDA	514,482	414,509	263,140	375,874	402,634
EBITDA Margin (%)	46.9	43.1	38.5	43.8	44.5
APAT	272,569	172,377	89,645	175,494	187,381
EPS (Rs)	21.7	13.7	7.1	13.9	14.9
EPS (% chg)	38.0	(36.8)	(48.0)	95.8	6.8
ROE (%)	13.9	9.7	4.5	8.6	8.8
P/E (x)	5.4	8.5	16.3	8.3	7.8
EV/EBITDA (x)	3.2	4.1	6.3	4.4	3.9
P/BV (x)	0.7	0.8	0.7	0.7	0.7

Source: Company, Emkay Research

CMP Rs 116 as of (May 18, 2021)	Target Price Rs 130 (∎) <sup>12 months</sup>
Rating	Upside
BUY (∎)	11.8 %

#### Change in Estimates

EPS Chg FY2	1E/F	(22E (	%)	-/-
Target Price of	hange	e (%)		NA
Target Period	(Mon	ths)		12
Previous Reco	c			BUY
Emkay vs Co	nsen	sus		
E	EPS E	stimat	es	
		F	Y21E	FY22E
Emkay			7.1	13.9
Consensus			12.9	13.1
Mean Consen	sus T	P (12N	1)	Rs 129
Stock Details	;			
Bloomberg Code ONGC IN				
Face Value (F	Rs)			5
Shares outsta	nding	(mn)		12,580
52 Week H/L				122 / 64
M Cap (Rs bn	/USD	bn)	1,46′	1 / 20.00
Daily Avg Volu	ume (ı	nos.)	34	,098,700
Daily Avg Tur	nover	(US\$ r	nn)	51.6
Shareholding	9 Patt	ern Ma	ar '21	
Promoters	-			60.4%
Flls				8.1%
DIIs				17.5%
Public and Ot	hers			14.0%
Price Perform	nance	•		
(%)	1M	3M	6M	12M
Absolute	8	5	61	59
Rel. to Nifty	5	5	38	(7)
Relative price	e cha	rt		
125 <sub>]</sub> Rs				% [ 10
112 -			M	<u>م</u> الم
99 - 1		٨	1 JAM	<b>~</b> ↓ -10
			VI. J	W 20
86 - 1/21	L.	J	Υγr `	
86	Lyn,	Ju	W	30
73 -	Lyn Lyn	, flu	W	30
73	•	ov-20 Jai		30 -40 21May-21
73	C (LHS)	ov-20 Jan	n-21 Mar-: — Rel to N	30 -40 21May-21
73	erg berg by prod s) are n	luced by	Emkay Cole for the	30 40 21 May-21 ifty (RHS) Global. The
73 60 May-20 Jul-20 S Cource: Bloomt This report is sole following person(	c (LHS) berg ely prod s) are r recom	luced by	Emkay Cole for the	30 40 21 May-21 ifty (RHS) Global. The
73	c (LHS) berg ely prod s) are r recom	luced by esponsil mendatio	Emkay Cole for the	30 40 21 May-21 why (RHS) Global. The e
73 May-20 Jul-20 S Source: Bloomb Source: Bloomb following person( production of the Sabri Hazarik	c (LHS) Derg ely prod s) are r recom a (2) a eml	luced by esponsil mendatio	Emkay Cole for the	30 40 21 May-21 why (RHS) Global. The e

#### Tanay Gabhawala


tanay.gabhawala@emkayglobal.com +91 22 6612 1336

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

## **Story in Charts**

Exhibit 1: Spot benchmarks imply a domestic gas price of USD4.4/mmbtu GCV					
USD/mmbtu	Volume Share	Netback			
Henry Hub	43%	2.5			
Canada	6%	2.0			
NBP	31%	9.5			
Russia	20%	1.0			
Blended Domestic Gas Price		4.4			


Source: BP, Bloomberg, Emkay Research



Source: Bloomberg, Emkay Research

Source: PPAC, Emkay Research

#### Exhibit 4: EV/EBITDA Band Chart - ONGC's valuation is attractive



Source: Bloomberg, Emkay Research

#### Exhibit 5: Value of investments

Rs/sh/mn	Shares (mn)	Price	Value
MRPL - CMP	1,255	35	43,937
PLNG - CMP	188	240	45,000
IOCL - CMP	1,337	95	127,034
GAIL - CMP	217	130	28,236
HPCL - CMP	779	225	175,256
Total			419,463

Source: Company, Emkay Research

#### **Exhibit 6: SOTP valuation**

Mar'23 Estimates (Rs bn)	Earnings/Value	Multiple (x)	EV/FV	Value/sh
Standalone				
EV/EBITDA Valuation	403	4.0	1,611	128
Less: Net Debt (Mar'22E End)			188	15
FV			1,423	113
Listed Investments - 50% Hair Cut	419	50%	210	17
Target Price			1,632	130
Source: Company, Emkay Research				

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

### Key Financials (Standalone)

#### **Income Statement**

Y/E Mar (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Revenue	1,096,546	962,136	682,911	857,688	903,980
Expenditure	582,063	547,627	419,771	481,814	501,346
EBITDA	514,482	414,509	263,140	375,874	402,634
Depreciation	154,561	186,169	163,992	180,402	197,267
EBIT	359,921	228,340	99,148	195,472	205,367
Other Income	72,653	61,050	52,532	55,736	61,624
Interest expenses	24,921	28,237	17,882	16,589	16,483
РВТ	407,653	261,154	133,799	234,618	250,509
Тах	132,645	69,241	44,925	59,124	63,128
Extraordinary Items	(7,362)	(57,467)	(12,380)	0	0
Minority Int./Income from Assoc.	0	0	0	0	0
Reported Net Income	267,646	134,445	76,494	175,494	187,381
Adjusted PAT	272,569	172,377	89,645	175,494	187,381

#### Balance Sheet

Y/E Mar (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Equity share capital	62,902	62,902	62,902	62,902	62,902
Reserves & surplus	1,954,994	1,880,479	1,925,305	2,021,827	2,124,886
Net worth	2,017,896	1,943,381	1,988,206	2,084,728	2,187,787
Minority Interest	0	0	0	0	0
Loan Funds	215,936	237,757	220,000	195,000	125,000
Net deferred tax liability	274,261	263,441	259,816	256,118	252,347
Total Liabilities	2,508,093	2,444,579	2,468,022	2,535,847	2,565,134
Net block	1,219,357	1,276,991	1,320,506	1,376,445	1,409,733
Investment	1,143,770	1,057,702	1,061,036	1,064,403	1,067,804
Current Assets	283,451	269,860	204,102	238,938	253,388
Cash & bank balance	5,041	9,682	19,432	7,005	8,936
Other Current Assets	110,632	121,620	86,324	108,417	114,269
<b>Current liabilities &amp; Provision</b>	488,988	522,229	483,500	513,476	539,023
Net current assets	(205,537)	(252,369)	(279,398)	(274,539)	(285,635)
Misc. exp	0	0	0	0	0
Total Assets	2,508,093	2,444,579	2,468,022	2,535,847	2,565,134

Cash Flow					
Y/E Mar (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
PBT (Ex-Other income) (NI+Dep)	335,000	200,104	81,267	178,882	188,884
Other Non-Cash items	84,242	103,334	(12,380)	0	0
Chg in working cap	(32,636)	40,654	33,153	(20,984)	9,257
Operating Cashflow	423,038	577,853	238,870	295,647	348,642
Capital expenditure	(174,301)	(255,555)	(211,130)	(240,000)	(234,250)
Free Cash Flow	248,737	322,298	27,740	55,647	114,392
Investments	3,227	86,068	(3,334)	(3,367)	(3,401)
Other Investing Cash Flow	(127,406)	(237,303)	118	119	121
Investing Cashflow	(225,827)	(345,740)	(161,814)	(187,512)	(175,906)
Equity Capital Raised	(1,265)	0	0	0	0
Loans Taken / (Repaid)	(39,986)	21,821	(17,757)	(25,000)	(70,000)
Dividend paid (incl tax)	(40,220)	0	0	0	0
Other Financing Cash Flow	(95,905)	(221,055)	(31,668)	(78,973)	(84,321)
Financing Cashflow	(202,297)	(227,471)	(67,307)	(120,562)	(170,804)
Net chg in cash	(5,086)	4,642	9,750	(12,427)	1,932
Opening cash position	10,127	5,041	9,682	19,432	7,005
Closing cash position	5,041	9,682	19,432	7,005	8,936

Source: Company, Emkay Research


Profitability (%)	FY19	FY20	FY21E	FY22E	FY23E
EBITDA Margin	46.9	43.1	38.5	43.8	44.5
EBIT Margin	32.8	23.7	14.5	22.8	22.7
Effective Tax Rate	32.5	26.5	33.6	25.2	25.2
Net Margin	25.1	19.9	13.0	20.5	20.7
ROCE	17.4	11.7	6.2	10.0	10.5
ROE	13.9	9.7	4.5	8.6	8.8
RoIC	36.9	22.6	9.7	18.5	18.6
Par Share Data (Da)	EV40	EV20	EVOAE	EVO2E	FY23E
Per Share Data (Rs) EPS	<b>FY19</b> 21.7	FY20	FY21E	FY22E	14.9
		13.7	7.1	13.9	
CEPS	34.1	30.1	20.1	28.3	30.6
BVPS	160.4	154.5	158.0	165.7	173.9
DPS	7.0	5.0	2.5	6.3	6.7
Valuations (x)	FY19	FY20	FY21E	FY22E	FY23E
PER	5.4	8.5	16.3	8.3	7.8
P/CEPS	3.4	3.9	5.8	4.1	3.8
P/BV	0.7	0.8	0.7	0.7	0.7
EV / Sales	1.5	1.8	2.4	1.9	1.8
EV / EBITDA	3.2	4.1	6.3	4.4	3.9
Dividend Yield (%)	6.0	4.3	2.2	5.4	5.8
Cooring Potio (x)	FY19	FY20	FY21E	FY22E	FY23E
Gearing Ratio (x)					
Net Debt/ Equity	0.1	0.1	0.1	0.1	0.1
Net Debt/EBIDTA	0.4	0.6	0.8	0.5	0.3
Working Cap Cycle (days)	(1.6)	3.2	2.3	5.1	4.7
Growth (%)	FY19	FY20	FY21E	FY22E	FY23E
Revenue			(22.2)	05.0	<b>F</b> 4
	29.0	(12.3)	(29.0)	25.6	5.4
EBITDA	29.0 38.0	(12.3) (19.4)	(29.0) (36.5)	42.8	
EBITDA EBIT		. ,	· ,		7.1
	38.0	(19.4)	(36.5)	42.8	7.1 5.1
EBIT PAT	38.0 57.8 34.2	(19.4) (36.6) (49.8)	(36.5) (56.6) (43.1)	42.8 97.2 129.4	7.1 5.1 6.8
EBIT PAT Quarterly (Rs mn)	38.0 57.8 34.2 <b>Q3FY20</b>	(19.4) (36.6) (49.8) <b>Q4FY20</b>	(36.5) (56.6) (43.1) <b>Q1FY21</b>	42.8 97.2 129.4 <b>Q2FY21</b>	7.1 5.1 6.8 <b>Q3FY21</b>
EBIT PAT Quarterly (Rs mn) Revenue	38.0 57.8 34.2 <b>Q3FY20</b> 237,101	(19.4) (36.6) (49.8) <b>Q4FY20</b> 214,562	(36.5) (56.6) (43.1) <b>Q1FY21</b> 130,113	42.8 97.2 129.4 <b>Q2FY21</b> 169,171	7.1 5.1 6.8 <b>Q3FY21</b> 170,238
EBIT PAT Quarterly (Rs mn) Revenue EBITDA	38.0 57.8 34.2 <b>Q3FY20</b> 237,101 105,795	(19.4) (36.6) (49.8) <b>Q4FY20</b> 214,562 55,495	(36.5) (56.6) (43.1) <b>Q1FY21</b> 130,113 47,808	42.8 97.2 129.4 <b>Q2FY21</b> 169,171 69,894	7.1 5.1 6.8 <b>Q3FY21</b> 170,238 65,076
EBIT PAT Quarterly (Rs mn) Revenue EBITDA EBITDA Margin (%)	38.0 57.8 34.2 <b>Q3FY20</b> 237,101 105,795 <b>44.6</b>	(19.4) (36.6) (49.8) <b>Q4FY20</b> 214,562 55,495 <b>25.9</b>	(36.5) (56.6) (43.1) <b>Q1FY21</b> 130,113 47,808 <b>36.7</b>	42.8 97.2 129.4 <b>Q2FY21</b> 169,171 69,894 <b>41.3</b>	7.1 5.1 6.8 <b>Q3FY21</b> 170,238 65,076 <b>38.2</b>
EBIT PAT Quarterly (Rs mn) Revenue EBITDA EBITDA Margin (%) PAT	38.0 57.8 34.2 <b>Q3FY20</b> 237,101 105,795 <b>44.6</b> 42,265	(19.4) (36.6) (49.8) <b>Q4FY20</b> 214,562 55,495 <b>25.9</b> (30,983)	(36.5) (56.6) (43.1) <b>Q1FY21</b> 130,113 47,808 <b>36.7</b> 4,960	42.8 97.2 129.4 <b>Q2FY21</b> 169,171 69,894 <b>41.3</b> 28,778	7.1 5.1 6.8 <b>Q3FY21</b> 170,238 65,076 <b>38.2</b> 13,782
EBIT PAT Quarterly (Rs mn) Revenue EBITDA EBITDA Margin (%)	38.0 57.8 34.2 <b>Q3FY20</b> 237,101 105,795 <b>44.6</b>	(19.4) (36.6) (49.8) <b>Q4FY20</b> 214,562 55,495 <b>25.9</b>	(36.5) (56.6) (43.1) <b>Q1FY21</b> 130,113 47,808 <b>36.7</b>	42.8 97.2 129.4 <b>Q2FY21</b> 169,171 69,894 <b>41.3</b>	7.1 5.1 6.8 <b>Q3FY21</b> 170,238 65,076 <b>38.2</b> 13,782
EBIT PAT Quarterly (Rs mn) Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs)	38.0 57.8 34.2 <b>Q3FY20</b> 237,101 105,795 <b>44.6</b> 42,265	(19.4) (36.6) (49.8) <b>Q4FY20</b> 214,562 55,495 <b>25.9</b> (30,983)	(36.5) (56.6) (43.1) <b>Q1FY21</b> 130,113 47,808 <b>36.7</b> 4,960	42.8 97.2 129.4 <b>Q2FY21</b> 169,171 69,894 <b>41.3</b> 28,778	7.1 5.1 6.8 <b>Q3FY21</b> 170,238 65,076 <b>38.2</b> 13,782 <b>1.1</b>
EBIT PAT Quarterly (Rs mn) Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs) Source: Company, Emkay Research	38.0 57.8 34.2 <b>Q3FY20</b> 237,101 105,795 <b>44.6</b> 42,265 <b>3.4</b>	(19.4) (36.6) (49.8) <b>Q4FY20</b> 214,562 55,495 <b>25.9</b> (30,983) (2.5)	(36.5) (56.6) (43.1) <b>Q1FY21</b> 130,113 47,808 <b>36.7</b> 4,960 <b>0.4</b>	42.8 97.2 129.4 <b>Q2FY21</b> 169,171 69,894 <b>41.3</b> 28,778 <b>2.3</b>	7.1 5.1 6.8 <b>Q3FY21</b> 170,238 65,076 <b>38.2</b> 13,782 <b>1.1</b> Mar-21
EBIT PAT Quarterly (Rs mn) Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs) Source: Company, Emkay Research Shareholding Pattern (%)	38.0 57.8 34.2 <b>Q3FY20</b> 237,101 105,795 <b>44.6</b> 42,265 <b>3.4</b> Mar-20	(19.4) (36.6) (49.8) <b>Q4FY20</b> 214,562 55,495 <b>25.9</b> (30,983) (2.5) <b>Jun-20</b>	(36.5) (56.6) (43.1) <b>Q1FY21</b> 130,113 47,808 <b>36.7</b> 4,960 <b>0.4</b> <b>Sep-20</b>	42.8 97.2 129.4 <b>Q2FY21</b> 169,171 69,894 <b>41.3</b> 28,778 <b>2.3</b> <b>Dec-20</b>	7.1 5.1 6.8 <b>Q3FY21</b> 170,238 65,076 <b>38.2</b> 13,782 <b>1.1</b> <b>Mar-21</b> 60.4
EBIT PAT Quarterly (Rs mn) Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs) Source: Company, Emkay Research Shareholding Pattern (%) Promoters	38.0 57.8 34.2 <b>Q3FY20</b> 237,101 105,795 <b>44.6</b> 42,265 <b>3.4</b> <b>Mar-20</b> 60.4	(19.4) (36.6) (49.8) <b>Q4FY20</b> 214,562 55,495 <b>25.9</b> (30,983) (2.5) <b>Jun-20</b> 60.4	(36.5) (56.6) (43.1) <b>Q1FY21</b> 130,113 47,808 <b>36.7</b> 4,960 <b>0.4</b> <b>Sep-20</b> 60.4	42.8 97.2 129.4 <b>Q2FY21</b> 169,171 69,894 <b>41.3</b> 28,778 <b>2.3</b> <b>Dec-20</b> 60.4	5.4 7.1 5.1 6.8 <b>Q3FY21</b> 170,238 65,076 <b>38.2</b> 13,782 <b>13,782</b> <b>13,782</b> <b>14,1</b> 60,4 8.1 17,5

Source: Capitaline

#### RECOMMENDATION HISTORY TABLE

Date	Closing Price	ТР	Period (months)	Rating	Analyst
23-Apr-21	102	130	12m	Buy	Sabri Hazarika
23-Mar-21	107	130	12m	Buy	Sabri Hazarika
18-Feb-21	111	130	12m	Buy	Sabri Hazarika
15-Feb-21	97	130	12m	Buy	Sabri Hazarika
6-Jan-21	95	100	12m	Buy	Sabri Hazarika
26-Nov-20	79	100	12m	Buy	Sabri Hazarika
17-Nov-20	70	100	12m	Buy	Sabri Hazarika
27-Oct-20	66	100	12m	Buy	Sabri Hazarika
28-Sep-20	71	100	12m	Buy	Sabri Hazarika
2-Aug-20	77	100	12m	Buy	Sabri Hazarika
1-Jul-20	79	105	12m	Buy	Sabri Hazarika
6-May-20	78	100	12m	Buy	Sabri Hazarika
11-Mar-20	66	100	12m	Buy	Sabri Hazarika
16-Feb-20	95	150	12m	Buy	Sabri Hazarika
24-Jan-20	108	170	12m	Buy	Sabri Hazarika
20-Dec-19	115	170	12m	Buy	Sabri Hazarika
4-Dec-19	119	180	12m	Buy	Sabri Hazarika
16-Nov-19	124	180	12m	Buy	Sabri Hazarika
25-Oct-19	128	190	12m	Buy	Sabri Hazarika
23-Sep-19	125	190	12m	Buy	Sabri Hazarika
13-Aug-19	116	185	12m	Buy	Sabri Hazarika
10-Jun-19	150	190	12m	Buy	Sabri Hazarika
3-Jun-19	157	190	12m	Buy	Sabri Hazarika

**RECOMMENDATION HISTORY CHART** 



Source: Bloomberg, Company, Emkay Research

Source: Company, Emkay Research



#### Analyst: Sabri Hazarika

#### **Contact Details**

sabri.hazarika@emkayglobal.com +91 22 6612 1282

#### Sector

Oil & Gas

#### Analyst bio

Sabri Hazarika holds an MBA and comes with 11 years of research experience. His team currently covers 12 stocks in the Indian Oil & Gas space.

# Emkay Alpha Portfolio – Oil & Gas

EAP sector portfolio

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight (Normalised)
Oil & Gas	9.92	9.91	0%	0	100.00
BPCL	0.42	0.46	10%	4	4.68
GAIL	0.33	0.37	12%	4	3.68
Gujarat Gas	0.11	0.00	-100%	-11	0.00
Gujarat State Petronet	0.09	0.05	-46%	-4	0.51
Gulf Oil Lubricants	0.00	0.03	NA	3	0.30
HPCL	0.22	0.24	10%	2	2.40
Indian Oil	0.31	0.29	-5%	-2	2.92
Indraprastha Gas	0.21	0.23	11%	2	2.37
Petronet LNG	0.21	0.24	10%	2	2.37
Oil India	0.06	0.06	0%	0	0.56
ONGC	0.49	0.54	10%	5	5.47
Reliance Industries	7.48	7.41	-1%	-7	74.72
Cash	0.00	0.00	NA	0	0.03

Source: Emkay Research

\* Not under coverage: Equal Weight

High Conviction/Strong Over Weight

#### Sector portfolio NAV

	Base					Latest
	1-Apr-19	18-May-20	17-Nov-20	15-Feb-21	16-Apr-21	17-May-21
EAP - Oil & Gas	100.0	90.3	121.0	127.0	122.8	126.1
BSE200 Neutral Weighted Portfolio (ETF)	100.0	90.2	120.1	126.2	122.1	125.4
*Derfermence measurement bees date 1st						


\*Performance measurement base date 1<sup>st</sup> April 2019 Source: Emkay Research

#### Price Performance (%)

	1m	3m	6m	12m
EAP - Oil & Gas	2.7%	-0.7%	4.2%	39.7%
BSE200 Neutral Weighted Portfolio (ETF)	2.8%	-0.6%	4.5%	39.1%

Source: Emkay Research





Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): Nifty

Please see our model portfolio (Emkay Alpha Portfolio): SMID

"Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals"

#### **Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.	
BUY	Over 15%	
HOLD	Between -5% to 15%	
SELL	Below -5%	

Completed Date: 19 May 2021 04:06:36 (SGT) Dissemination Date: 19 May 2021 04:07:36 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

#### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

• This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.

• Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

**Disclaimer for U.S. persons only:** This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

#### ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate<sup>1</sup> does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

#### COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of May 19, 2021
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of May 19, 2021.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the May 19, 2021
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the May 19, 2021

RESTRICTIONS ON D	DISTRIBUTION
General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 <sup>th</sup> Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

#### Emkay Global Financial Services Ltd. CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com